The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Cystic Fibrosis Foundation Pulmonary Guideline. Pharmacologic Approaches to Prevention and Eradication of Initial Pseudomonas aeruginosa Infection
Abstract
Description: The Cystic Fibrosis (CF) Foundation developed clinical care guidelines for the prevention of Pseudomonas aeruginosa infection, the treatment of initial P. aeruginosa infection, and the use of bronchoscopy to obtain routine airway cultures in individuals with CF. Methods: A multidisciplinary committee developed questions about the prevention and treatment of initial P. aeruginosa infection and the use of bronchoscopy to obtain routine airway cultures. The outcome measure of interest was cultures without P. aeruginosa growth. Systematic reviews of PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials were conducted in May 2012 and August 2013. Searches combined controlled vocabulary terms and text words for CF and terms relevant to each question. The entire committee reviewed the evidence, and final recommendation statements were graded using the U.S. Preventive Services Task Force system. Recommendation 1: The CF Foundation strongly recommends inhaled antibiotic therapy for the treatment of initial or new growth of P. aeruginosa from an airway culture (certainty of net benefit, high; estimate of net benefit, substantial; grade of recommendation, A). The favored antibiotic regimen is inhaled tobramycin (300 mg twice daily) for 28 days. Recommendation 2: The CF Foundation recommends against the use of prophylactic antipseudomonal antibiotics to prevent the acquisition P. aeruginosa (certainty of net benefit, moderate; estimate of net benefit, zero; grade of recommendation, D). Recommendation 3: The CF Foundation recommends routine oropharyngeal cultures rather than bronchoalveolar lavage cultures obtained by bronchoscopy in individuals with CF who cannot expectorate sputum to determine if they are infected with P. aeruginosa (certainty of net benefit, moderate; estimate of net benefit, moderate; grade of recommendation, B).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Emerson, J., Rosenfeld, M., McNamara, S., Ramsey, B., & Gibson, R. L. (2002) · Pediatric Pulmonology · doi:10.1002/ppul.10127 · Cited by 1,007
Self-citationAdaptation of Pseudomonas aeruginosa to the cystic fibrosis airway: an evolutionary perspective
Folkesson, A., Jelsbak, L., Yang, L., Johansen, H. K., Ciofu, O., Høiby, N., & Molin, S. (2012) · Nature Reviews Microbiology · doi:10.1038/nrmicro2907 · Cited by 715
Longitudinal Assessment of Pseudomonas aeruginosa in Young Children with Cystic Fibrosis
Burns, J. L., Gibson, R. L., McNamara, S., Yim, D., Emerson, J., Rosenfeld, M., Hiatt, P., McCoy, K., Castile, R., Smith, A. L., et al. (2001) · The Journal of Infectious Diseases · doi:10.1086/318075 · Cited by 555
Self-citationPrevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment
Valerius, N. H., Koch, C., & Høiby, N. (1991) · The Lancet · doi:10.1016/0140-6736(91)91446-2 · Cited by 475
Treatment of lung infection in patients with cystic fibrosis: Current and future strategies
Döring, G., Flume, P., Heijerman, H., & Elborn, J. S. (2012) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2012.10.004 · Cited by 474
Frederiksen, B., Koch, C., & Høiby, N. (1997) · Pediatric Pulmonology · doi:10.1002/(sici)1099-0496(199705)23:5<330::aid-ppul4>3.0.co;2-o · Cited by 473
Infection Prevention and Control Guideline for Cystic Fibrosis: 2013 Update
Saiman, L., Siegel, J. D., LiPuma, J. J., Brown, R. F., Bryson, E. A., Chambers, M. J., Downer, V. S., Fliege, J., Hazle, L. A., Jain, M., et al. (2014) · Infection Control & Hospital Epidemiology · doi:10.1086/676882 · Cited by 387
Self-citationSignificant Microbiological Effect of Inhaled Tobramycin in Young Children with Cystic Fibrosis
Gibson, R. L., Emerson, J., McNamara, S., Burns, J. L., Rosenfeld, M., Yunker, A., Hamblett, N., Accurso, F., Dovey, M., Hiatt, P., et al. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200208-855oc · Cited by 318
Self-citationArmstrong, D. S., Grimwood, K., Carlin, J. B., Carzino, R., Olinsky, A., & Phenlan, P. D. (1996) · Pediatric Pulmonology · doi:10.1002/(sici)1099-0496(199605)21:5<267::aid-ppul1>3.0.co;2-k · Cited by 301
Ratjen, F., Munck, A., Kho, P., Angyalosi, G., & for the ELITE Study Group (2010) · Thorax · doi:10.1136/thx.2009.121657 · Cited by 291
Self-citation
Cited by
Elborn, J. S. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00576-6 · Cited by 1,805
The future of cystic fibrosis care: a global perspective
Bell, S. C., Mall, M. A., Gutierrez, H., Macek, M., Madge, S., Davies, J. C., Burgel, P.-R., Tullis, E., Castaños, C., Castellani, C., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30337-6 · Cited by 974
Self-citationThe Epidemiology and Pathogenesis and Treatment of Pseudomonas aeruginosa Infections: An Update
Reynolds, D., & Kollef, M. (2021) · Drugs · doi:10.1007/s40265-021-01635-6 · Cited by 721
Hisert, K. B., Heltshe, S. L., Pope, C., Jorth, P., Wu, X., Edwards, R. M., Radey, M., Accurso, F. J., Wolter, D. J., Cooke, G., et al. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201609-1954oc · Cited by 389
Grasemann, H., & Ratjen, F. (2023) · New England Journal of Medicine · doi:10.1056/nejmra2216474 · Cited by 334
Self-citation
Metadata
- Authors
- Mogayzel, P. J., Naureckas, E. T., Robinson, K. A., Brady, C., Guill, M., Lahiri, T., Lubsch, L., Matsui, J., Oermann, C. M., Ratjen, F., Rosenfeld, M., Simon, R. H., Hazle, L., Sabadosa, K., & Marshall, B. C.
- Venue
- Annals of the American Thoracic Society
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-12-01
- Volume
- 11
- Issue
- 10
- Pages
- 1640-1650
- ISSN
- 2325-6621 (ISSN-L)
- 2329-6933
- OpenAlex
- W2168898577
- Cited by
- 269
- References
- 35
- FWCI
- 13.09
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cystic Fibrosis Foundation Pulmonary Guideline. Pharmacologic Approaches to Prevention and Eradication of Initial Pseudomonas aeruginosa Infection. https://app.cochat.ai/papers/10.1513/annalsats.201404-166oc
- The paper
- Mogayzel, P. J., Naureckas, E. T., Robinson, K. A., Brady, C., Guill, M., Lahiri, T., Lubsch, L., Matsui, J., Oermann, C. M., Ratjen, F., Rosenfeld, M., Simon, R. H., Hazle, L., Sabadosa, K., & Marshall, B. C. (2014). Cystic Fibrosis Foundation Pulmonary Guideline. Pharmacologic Approaches to Prevention and Eradication of Initial Pseudomonas aeruginosa Infection. Annals of the American Thoracic Society. https://doi.org/10.1513/annalsats.201404-166oc
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.